Is Heron Therapeutics, Inc. (HRTX) a Buy, Sell, or Hold?
Heron Therapeutics, Inc.
NASDAQ:HRTX
$0.4299 USD
$0.01 (3.12%)
- Volume
- 3.55M
- Average Volume
- 3.39M
- Market Capitalization
- $67.9M
- P/E Ratio
- -2.43
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $2.13
- Year Low
- $0.38
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.53
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Craig Alexander Collard |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | HRTX |
| CUSIP | 427746102 |
| CIK | 0000818033 |
| Web | https://www.herontx.com |
| Phone | 858 251 4400 |
| Currency | USD |
| Employees | 128 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 15.50 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.53 |
| Quick Ratio | 1.51 |
| Cash Ratio | 0.29 |
Sales & Book Value
| Annual Sales | $154.9M |
| Price / Sales | 0.45 |
| Cash Flow | -0.11 |
| Price / Cash Flow | -3.25 |
| Price / Book | 8.92 |
Price Target and Rating
| Average Stock Price Forecast | $6.00 |
| High Stock Price Forecast | $9.00 |
| Low Stock Price Forecast | $5.00 |
| Forecast Upside/Downside | -92.84% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 19 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.12 |
| Trailing P/E Ratio | -2.43 |
| PEG Ratio | 0.01 |
| P/E Growth | 0.01 |
| Net Income | $-20.2M |
| Net Margin | -20.53% |
| Pretax Margin | -20.53% |
| Return on Equity | -1115.29% |
| Return on Assets | -12.57% |
Financials Score
| AltmanZ Score | -9.98 |
| Piotroski Score | 3.00 |
| Working Capital | 138.47M |
| Total Assets | 246.22M |
| Ebit | -27.04M |
| Market Cap | 67.9M |
| Total Liabilities | 237.08M |
Poll Results
About Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepi ... tant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
New Strong Sell Stocks for July 15th
2026-07-15 07:26:08
BV, RAIL and HRTX have been added to the Zacks Rank #5 (Strong Sell) List on July 15th, 2026.
U.S. District Court Issues Decision Regarding CINVANTI® Patents
2026-06-02 08:12:00
CARY, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the U.S. District Court for the District of Delaware issued a decision in the patent litigation between Heron and Azurity Pharmaceuticals, Inc., Azurity Pharmaceuticals India LLP f/k/a Slayback Pharma India LLP, and Slayback Pharma LLC (“Azurity”), with respect to CINVANTI® (aprepitant) injectable emulsion, holding that the asserted claims of Company's U.S. Patent Nos. 12,115,255 and 12,290,520 are invalid.
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
2026-05-11 13:20:47
Heron Therapeutics, Inc. (HRTX) Q1 2026 Earnings Call Transcript
Heron Therapeutics Q1 Earnings Call Highlights
2026-05-11 11:08:39
Heron Therapeutics NASDAQ: HRTX said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter.
Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say
2026-05-11 10:31:24
The headline numbers for Heron Therapeutics (HRTX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Heron Therapeutics (HRTX) Reports Q1 Loss, Lags Revenue Estimates
2026-05-11 10:11:14
Heron Therapeutics (HRTX) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to earnings of $0.01 per share a year ago.
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
2026-05-11 08:00:00
CARY, N.C., May 11, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced financial results for the three months ended March 31, 2026, and highlighted recent corporate updates.
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
2026-05-04 11:00:29
Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Frequently Asked Questions
-
What is the current Heron Therapeutics, Inc. (HRTX) stock price?
-
Heron Therapeutics, Inc.(NASDAQ:HRTX) stock price is $0.4299 in the last trading session. During the trading session, HRTX stock reached the peak price of $2.13 while $0.38 was the lowest point it dropped to. The percentage change in HRTX stock occurred in the recent session was 3.12% while the dollar amount for the price change in HRTX stock was $0.01.
-
HRTX's industry and sector of operation?
-
The NASDAQ listed HRTX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of HRTX?
-
William Forbes D. | Executive Vice President & Chief Development Officer
Craig Alexander Collard | Chief Executive Officer & Director
Mark E. Hensley | Executive Vice President & Chief Operating Officer
Jeff Cohn | Executive Director, Assistant General Counsel & Assistant Secretary
Ryan Craig | Vice President of Marketing -
How many employees does HRTX have?
-
Number of HRTX employees currently stands at 128. HRTX operates from 4242 Campus Point Court, Cary, NC 92121, US.
-
Link for HRTX official website?
-
Official Website of HRTX is: https://www.herontx.com
-
How do I contact HRTX?
-
HRTX could be contacted at phone #858 251 4400 and can also be accessed through its website. HRTX operates from 4242 Campus Point Court, Cary, NC 92121, US.
-
How many shares of HRTX are traded daily?
-
The average number of HRTX shares traded daily for last 3 months was 3.39M.
-
What is the market cap of HRTX currently?
-
The market value of HRTX currently stands at $67.9M with its latest stock price at $0.4299